Online inquiry

IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4307MR)

This product GTTS-WQ4307MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C1S gene. The antibody can be applied in Cold agglutinin disease (CAD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346850.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 716
UniProt ID P09871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4307MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12302MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ9274MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ9954MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ6942MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ1157MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ4383MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ12104MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ2824MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW